Equity Profile

GILD

Gilead Sciences, Inc.

Health CareBiotechnology$163.1B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Gilead Sciences, Inc. is a biotechnology company focused on developing innovative medicines, particularly in the fields of HIV, liver diseases, and oncology....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and performance, and investors will be looking for continued growth.

N/A

Revenue Growth

Revenue growth is crucial for assessing the company's ability to expand its market share and sustain operations.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

GILD Q2-2026 Earnings Preview

Context

Company Snapshot

Gilead Sciences, Inc. is a biotechnology company focused on developing innovative medicines, particularly in the fields of HIV, liver diseases, and oncology. With a market cap of $163 billion, Gilead plays a significant role in the health care sector, addressing critical health challenges and advancing treatment options.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+11.92%

Avg Stock Reaction

-0.05%

Last Quarter Recap

In Q1-2026, Gilead reported an EPS of $2.03, surpassing estimates by 7.69%. However, the stock declined by 1.64% the following day, indicating mixed market sentiment.

Management Promises & Guidance

Focus on expanding its portfolio of antiviral therapies.
Commitment to enhancing research and development efforts.
Plans to improve patient access to its treatments.

Expectations

Wall Street Expectations

Overall expectations for Gilead's upcoming earnings report are cautious, given the mixed reactions to previous earnings despite consistent EPS beats.

Bull Case

If Gilead continues its trend of beating EPS estimates and shows strong revenue growth, it could signal robust demand for its products and lead to a positive stock reaction.

Bear Case

On the other hand, if revenue growth falls short or there are concerns about future product pipelines, this could lead to negative sentiment and a decline in stock value.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the reported revenue growth for Gilead's key antiviral therapies?

This figure will be critical in assessing the company's market performance and future growth potential.

How does management plan to address any potential challenges in product development?

Investors will be keen to hear about strategies to mitigate risks and ensure continued innovation.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Gilead's potential for revenue growth, particularly in its antiviral portfolio, which has shown resilience in previous quarters.

Supporting Evidence

Gilead has consistently beaten EPS estimates, indicating stronger-than-expected operational performance.

Options pricing suggests a higher expected move than historical averages, indicating potential for positive surprises.

Key Risk

If revenue growth comes in below 5%, it could challenge the current optimistic outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing Gilead's ability to sustain growth against potential challenges in its product pipeline.

Bull Confirmed If

A revenue growth rate of over 10% would confirm the bull case, indicating strong demand for Gilead's products.

Bear Confirmed If

Conversely, if revenue growth is below 5%, it would raise concerns about the company's future prospects.

Pre-Earnings Positioning

Options Market

Implied Move

±3.77%

Historical Avg

±1.2%

Pricing rich

The options market is pricing in a potential move of about 3.77%, indicating that traders expect some volatility around the earnings announcement.

Options are pricing ±3.8% while GILD has averaged ±1.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

22.3%

Calls (429K)P/C Ratio: 0.42Puts (148K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 14 of 29 (48%)

This setup has occurred 30 times across Health Care in the last 2 years. 14 of 29 faded and 15 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.7%, with a raw directional average of +2.7% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Gilead beats expectations and raises guidance, history suggests the stock could see an average one-day move of around +2.7%.

In-Line / Cautious

If results are in line with expectations but management's commentary is cautious, the stock may react neutrally.

Miss

If Gilead misses on revenue or EPS, the stock could decline, with historical patterns suggesting an average one-day move of -0.05%.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

D-NJJosh GottheimerRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the pipeline for new antiviral therapies.
2Insights on market demand for existing products.
3Management's perspective on competitive pressures in the biotechnology sector.
4Details on research and development investments.
5Any commentary on patient access initiatives.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

Gilead Sciences, Inc. is a biotechnology company focused on developing innovative medicines, particularly in the fields of HIV, liver diseases, and oncology....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and performance, and investors will be looking for continued growth.

N/A

Revenue Growth

Revenue growth is crucial for assessing the company's ability to expand its market share and sustain operations.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

GILD Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+11.92%

Avg Stock Reaction

-0.05%

Last Quarter Recap

In Q1-2026, Gilead reported an EPS of $2.03, surpassing estimates by 7.69%. However, the stock declined by 1.64% the following day, indicating mixed market sentiment.

Management Promises & Guidance

Focus on expanding its portfolio of antiviral therapies.
Commitment to enhancing research and development efforts.
Plans to improve patient access to its treatments.

Expectations

Wall Street Expectations

Overall expectations for Gilead's upcoming earnings report are cautious, given the mixed reactions to previous earnings despite consistent EPS beats.

Bull Case

If Gilead continues its trend of beating EPS estimates and shows strong revenue growth, it could signal robust demand for its products and lead to a positive stock reaction.

Bear Case

On the other hand, if revenue growth falls short or there are concerns about future product pipelines, this could lead to negative sentiment and a decline in stock value.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the reported revenue growth for Gilead's key antiviral therapies?

This figure will be critical in assessing the company's market performance and future growth potential.

How does management plan to address any potential challenges in product development?

Investors will be keen to hear about strategies to mitigate risks and ensure continued innovation.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Gilead's potential for revenue growth, particularly in its antiviral portfolio, which has shown resilience in previous quarters.

Supporting Evidence

Gilead has consistently beaten EPS estimates, indicating stronger-than-expected operational performance.

Options pricing suggests a higher expected move than historical averages, indicating potential for positive surprises.

Key Risk

If revenue growth comes in below 5%, it could challenge the current optimistic outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing Gilead's ability to sustain growth against potential challenges in its product pipeline.

Bull Confirmed If

A revenue growth rate of over 10% would confirm the bull case, indicating strong demand for Gilead's products.

Bear Confirmed If

Conversely, if revenue growth is below 5%, it would raise concerns about the company's future prospects.

Pre-Earnings Positioning

Options Market

Implied Move

±3.77%

Historical Avg

±1.2%

Pricing rich

The options market is pricing in a potential move of about 3.77%, indicating that traders expect some volatility around the earnings announcement.

Options are pricing ±3.8% while GILD has averaged ±1.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

22.3%

Calls (429K)P/C Ratio: 0.42Puts (148K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 14 of 29 (48%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Gilead beats expectations and raises guidance, history suggests the stock could see an average one-day move of around +2.7%.

In-Line / Cautious

If results are in line with expectations but management's commentary is cautious, the stock may react neutrally.

Miss

If Gilead misses on revenue or EPS, the stock could decline, with historical patterns suggesting an average one-day move of -0.05%.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

D-NJJosh GottheimerRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the pipeline for new antiviral therapies.
2Insights on market demand for existing products.
3Management's perspective on competitive pressures in the biotechnology sector.
4Details on research and development investments.
5Any commentary on patient access initiatives.